Sarcoidosis — Worldwide Sarcoidosis Research Study
Citation(s)
Aranda A, Paramo JA, Rocha E Fibrinolytic activity in plasma after gynecological and urological surgery. Haemostasis. 1988;18(2):129-34. doi: 10.1159/000215794.
Clark RE, McKnight RC, Kissane JM, Weldon CS Experimentally reversed pulmonary blood flow. Implications for the surgical management of complex forms of congenital heart disease. Ann Thorac Surg. 1975 Oct;20(4):433-45. doi: 10.1016/s0003-4975(10)64241-5.
Rybicki BA, Major M, Popovich J Jr, Maliarik MJ, Iannuzzi MC Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. Am J Epidemiol. 1997 Feb 1;145(3):234-41. doi: 10.1093/oxfordjournals.aje.a009096.
Statement on sarcoidosis Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med. 1999 Aug;160(2):736-55. doi: 10.1164/ajrccm.160.2.ats4-99. No abstract available.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
